Neuronetics (STIM) Earnings Date & Reports

Key Takeaways

• Total revenue rose 12.5% year over year to $41.96 million, ahead of consensus estimates near $40.9 million.
• Net loss narrowed sharply to $1.7 million, or $0.02 per share, from $9.0 million, or $0.13 per share, in the prior-year quarter.
• Gross margin expanded to 52.2% from 45.9%, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) turned positive at $1.9 million.
• Greenbrook clinic revenue grew 20.1% to $26.2 million, and NeuroStar revenue increased 1.8% to $15.8 million on record capital system sales.
• Full-year 2026 revenue guidance was maintained at $160 million to $164 million, while the gross margin outlook was raised to 49%–50%.
• For more details on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Neuronetics operates at the intersection of medical technology and mental health, selling its NeuroStar Advanced Therapy system while running the Greenbrook clinic network for transcranial magnetic stimulation (TMS) and other neurohealth treatments. This quarterly report matters because investors are watching whether the company can convert revenue growth into genuine profitability and positive cash flow after its December 2024 Greenbrook acquisition. The third quarter delivered meaningful progress on that front: margins widened, operating expenses declined, and adjusted EBITDA swung positive. With a transition toward purchase and lease options in its NeuroStar commercial model still underway, these results offer a key read on how effectively management is executing its integration and cost-optimization strategy.

Reported Results

For the third quarter ended September 30, 2026, Neuronetics reported total revenue of $41.96 million, up 12.5% from $37.3 million a year earlier and above consensus estimates of roughly $40.9 million. Greenbrook clinic revenue increased 20.1% to $26.2 million, while NeuroStar revenue rose 1.8% to $15.8 million, driven by record capital system sales that were partially offset by a decline in physician revenue during the go-to-market transition.

Gross margin improved to 52.2% from 45.9% in the prior-year quarter. Operating expenses fell 12.6% to $21.3 million from $24.4 million, primarily reflecting lower sales and marketing costs. The company reported income from operations of $5.0 million, compared with a loss from operations of $7.3 million a year ago. Net loss attributable to Neuronetics stockholders narrowed to $1.7 million, or $0.02 per share, versus $9.0 million, or $0.13 per share, in the prior-year period. Adjusted EBITDA was positive $1.9 million, an improvement of $6.6 million from a loss of $4.7 million.

Total cash stood at $27.9 million at quarter-end, consisting of $22.9 million in cash and cash equivalents and $5.8 million in restricted cash. For full-year 2026, management reaffirmed total revenue guidance of $160 million to $164 million, raised its gross margin outlook to 49%–50%, and narrowed its expected cash use from operating and investing activities.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Neuronetics, it offers a practical way to surface new opportunities and monitor signals across the market. Explore the AI Screener to streamline your research workflow.

Market Reaction and Investor Sentiment

Neuronetics entered this earnings cycle with sentiment focused on its path to profitability and cash-flow stability, and the third-quarter results provided several supportive signals. Revenue beat expectations, the loss per share came in far narrower than forecast, gross margin expanded, and the business generated positive cash flow from operating and investing activities for the quarter. The swing to positive adjusted EBITDA marked a notable milestone for a company that has historically reported losses. Investors were also watching the reiterated full-year revenue range and the improved gross margin guidance as evidence that cost discipline is taking hold. The key factors shaping interpretation include the durability of Greenbrook's clinic growth, the ongoing NeuroStar commercial-model transition, and the company's ability to sustain limited cash use through the second half of the year.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Neuronetics can sustain its improving trajectory. Management kept full-year 2026 revenue guidance at $160 million to $164 million while raising the gross margin target to 49%–50%, a signal that the mix of capital equipment sales and clinic services is evolving favorably.

Several operational catalysts are worth monitoring. The company submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for an accelerated TMS protocol, and a distribution agreement with Wave Neuroscience is intended to integrate its MeRT system with NeuroStar. These efforts could broaden the addressable patient population and expand the therapy platform over time.

Cost and cash management remain central themes. Management expects cash flow from operating and investing activities of negative $10 million to $12 million for the full year and continues to target limited to no net cash utilization in the second half. The continued rollout of SPRAVATO (esketamine) across the Greenbrook clinic network and the ramp of newly hired sales representatives, which management expects to contribute meaningfully by mid-2027, will be important indicators of whether revenue growth can keep pace with the company's profitability goals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations